Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
Efficacy of Prophylactic Oral Vancomycin in Preventing Recurrent Clostridium Difficile Infection in Hospitalized Patients Requiring Antibiotics
Sponsor: Renown Regional Medical Center
Listed as NCT03466502, this PHASE4 trial focuses on Clostridium Difficile Infection and remains completed. Sponsored by Renown Regional Medical Center, it has been updated 9 times since 2018, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Feb 2023 — Dec 2023 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE4
▶ Show 4 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
Status: Enrolling By Invitation → Active Not Recruiting
-
Nov 2019 — Dec 2020 [monthly]
Enrolling By Invitation PHASE4
-
Jun 2018 — Nov 2019 [monthly]
Enrolling By Invitation PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE4
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Renown Regional Medical Center
- University of Nevada, Reno
For direct contact, visit the study record on ClinicalTrials.gov .